Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Aleniglipron · GSBR-1290, GSBR-1001290

Small molecule · developed by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3 Most advanced trial

GPCR Developer

3 Registered trials

What is Aleniglipron?

Aleniglipron (GSBR-1290) is an oral agent given as capsules or tablets.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: GSBR-1290, GSBR-1001290
Drug type: Small molecule
Therapy area: Metabolic
Developer: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (GPCR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: Z6XCL6R9SX

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07654361	Phase 3	Obesity	Recruiting	GPCR
NCT05762471	Phase 1/2	Overweight or Obesity	Completed	GPCR
NCT06139055	Phase 1	Healthy Volunteers	Unknown	GPCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Weight ManagementObesityOverweightHealthy VolunteersOverweight or ObesityType2 Diabetes Mellitus

More from Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

ACCG-2671 Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GPCR page.

Follow GPCR, the company behind Aleniglipron

See GPCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GPCR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z